ABIVAX Société Anonyme’s Lock-Up Period Will Expire on April 17th (NASDAQ:ABVX)

ABIVAX Société Anonyme’s (NASDAQ:ABVX) lock-up period is set to end on Wednesday, April 17th. ABIVAX Société Anonyme had issued 18,699,460 shares in its public offering on October 20th. The total size of the offering was $216,913,736 based on an initial share price of $11.60. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analyst Weigh In

Separately, Morgan Stanley increased their price target on shares of ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday.

ABIVAX Société Anonyme Stock Performance

NASDAQ:ABVX opened at $15.00 on Friday. ABIVAX Société Anonyme has a 52 week low of $7.99 and a 52 week high of $17.02. The company’s 50-day simple moving average is $13.83.

Institutional Trading of ABIVAX Société Anonyme

Several institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC acquired a new position in shares of ABIVAX Société Anonyme during the 4th quarter worth approximately $249,000. Capstone Investment Advisors LLC acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at $618,000. Ghisallo Capital Management LLC purchased a new stake in ABIVAX Société Anonyme in the 4th quarter worth $642,000. Point72 Asset Management L.P. acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth $4,488,000. Finally, Citadel Advisors LLC acquired a new position in ABIVAX Société Anonyme during the fourth quarter worth $7,842,000. 47.91% of the stock is owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.